Benzamide, N-hydroxy-4-[(8-quinolinylamino)methyl]-, compd. with methanesulfonate (1:1)

Request For Quotation
Benzamide, N-hydroxy-4-[(8-quinolinylamino)methyl]-, compd. with methanesulfonate (1:1) Suppliers list
Company Name: BOC Sciences  
Tel: 1-631-485-4226; 16314854226
Email: info@bocsci.com
Company Name: TargetMol Chemicals Inc.  
Tel: 15002134094
Email: marketing@targetmol.cn
Company Name: TargetMol Chemicals Inc.  
Tel: 13564774135
Email: marketing@targetmol.com

Benzamide, N-hydroxy-4-[(8-quinolinylamino)methyl]-, compd. with methanesulfonate (1:1) manufacturers
Benzamide, N-hydroxy-4-[(8-quinolinylamino)methyl]-, compd. with methanesulfonate (1:1) Basic information
Product Name:Benzamide, N-hydroxy-4-[(8-quinolinylamino)methyl]-, compd. with methanesulfonate (1:1)
Synonyms:Benzamide, N-hydroxy-4-[(8-quinolinylamino)methyl]-, compd. with methanesulfonate (1:1);MPT0G211 mesylate
CAS:2151854-33-8
MF:C18H19N3O5S
MW:389.43
EINECS:
Product Categories:
Mol File:2151854-33-8.mol
Benzamide, N-hydroxy-4-[(8-quinolinylamino)methyl]-, compd. with methanesulfonate (1:1) Structure
Benzamide, N-hydroxy-4-[(8-quinolinylamino)methyl]-, compd. with methanesulfonate (1:1) Chemical Properties
Safety Information
MSDS Information
Benzamide, N-hydroxy-4-[(8-quinolinylamino)methyl]-, compd. with methanesulfonate (1:1) Usage And Synthesis
UsesMPT0G211 mesylate is a potent, orally active and selective HDAC6 inhibitor (IC50=0.291 nM). MPT0G211 mesylate displays >1000-fold selective for HDAC6 over other HDAC isoforms. MPT0G211 mesylate can penetrate the blood-brain barrier. MPT0G211 mesylate ameliorates tau phosphorylation and cognitive deficits in an Alzheimer’s disease model. MPT0G211 mesylate has anti-metastatic and neuroprotective effects. Anticancer activities[1][2][3].
in vivo

MPT0G211 mesylate (50 mg/kg; p.o.; daily for 3 months) significantly ameliorates the spatial memory impairment[1].
MPT0G211 mesylate (25 mg/kg; i.p.; qd; day 73 post-tumor injection) reduces numbers of nodules and lung weights[2].
MPT0G211 mesylate treatment not only diminishes tau phosphorylation by inhibition GSK3β activity but also enhances the acetylation of Hsp90, which causes the downregulation of HDAC6/Hsp90 binding and facilitates proteasomal degradation of polyubiquitinated p-tau[1].

Animal Model:Triple transgenic (3×Tg-AD) mice (harboring APPSwe and tauP301L mutant transgenes[1]
Dosage:50mg/kg
Administration:P.o.; daily for 3 months
Result:Significantly ameliorated the spatial memory impairment.
Animal Model:Female SCID mice (bearing MDA-MB-231 cells)[2]
Dosage:25mg/kg
Administration:I.p.; qd; day 73 post-tumor injection
Result:Significantly reduced numbers of nodules and lung weights.
IC 50HDAC6: 0.291 μM (IC50)
References[1] Fan SJ, et al. The novel histone de acetylase 6 inhibitor, MPT0G211, ameliorates tau phosphorylation and cognitive deficits in an Alzheimer's disease model. Cell Death Dis. 2018;9(6):655. Published 2018 May 29. DOI:10.1038/s41419-018-0688-5
[2] Hsieh YL, et al. Anti-metastatic activity of MPT0G211, a novel HDAC6 inhibitor, in human breast cancer cells in vitro and in vivo. Biochim Biophys Acta Mol Cell Res. 2019;1866(6):992-1003. DOI:10.1016/j.bbamcr.2019.03.003
[3] Tu HJ, et al. The anticancer effects of MPT0G211, a novel HDAC6 inhibitor, combined with chemotherapeutic agents in human acute leukemia cells. Clin Epigenetics. 2018;10(1):162. Published 2018 Dec 29. DOI:10.1016/j.bbamcr.2019.03.003
Benzamide, N-hydroxy-4-[(8-quinolinylamino)methyl]-, compd. with methanesulfonate (1:1) Preparation Products And Raw materials
Tag:Benzamide, N-hydroxy-4-[(8-quinolinylamino)methyl]-, compd. with methanesulfonate (1:1)(2151854-33-8) Related Product Information
Carbamazepine N-[2-Methyl-2-(2-phenyloxazol-4-yl)propyl]-3-[5-(trifluoroMethyl)-1,2,4-oxadiazol-3-yl]benzaMide Tucidinostat (Chidamide) LMK-235 4-Phenylbutyric acid Entinostat